FULVICIN P/G 330 Drug Patent Profile
✉ Email this page to a colleague
When do Fulvicin P/g 330 patents expire, and what generic alternatives are available?
Fulvicin P/g 330 is a drug marketed by Chartwell Rx and is included in one NDA.
The generic ingredient in FULVICIN P/G 330 is griseofulvin, ultramicrosize. There is one drug master file entry for this compound. Seven suppliers are listed for this compound. Additional details are available on the griseofulvin, ultramicrosize profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fulvicin P/g 330
A generic version of FULVICIN P/G 330 was approved as griseofulvin, ultramicrosize by MOUNTAIN on January 9th, 2014.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for FULVICIN P/G 330?
- What are the global sales for FULVICIN P/G 330?
- What is Average Wholesale Price for FULVICIN P/G 330?
Summary for FULVICIN P/G 330
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 76 |
| Patent Applications: | 4,486 |
| DailyMed Link: | FULVICIN P/G 330 at DailyMed |
Pharmacology for FULVICIN P/G 330
| Drug Class | Tubulin Inhibiting Agent |
| Physiological Effect | Decreased Mitosis Microtubule Inhibition |
US Patents and Regulatory Information for FULVICIN P/G 330
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chartwell Rx | FULVICIN P/G 330 | griseofulvin, ultramicrosize | TABLET;ORAL | 061996-004 | Apr 6, 1982 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
